Skip to main content

Table 1 Comparisons of the clinical characteristics between groups stratified by 28-days mortality

From: Comparing the impact on the prognosis of acute myocardial infarction critical patients of using midazolam, propofol, and dexmedetomidine for sedation

Variables

N = 427

28-days

p value

Mortality N = 102

Survival N = 325

MI

   

0.179

NSTEMI

121(28.3)

32(31.4)

89(27.4)

 

AWSTEMI

126(29.5)

35(34.3)

91(28.0)

 

NAWSTEMI

180(42.1)

35(34.3)

145(44.6)

 

Age, years

66.9 ± 12.3

69.4 ± 13.3

66.2 ± 11.9

0.020

Male, n(%)

304(71.8)

69(67.6)

238(73.2)

0.274

BMI, kg/m2

28.0 ± 5.5

28.1 ± 5.9

27.9 ± 5.4

0.871

Past medical history

    

Hypertension, n(%)

55(12.9)

23(22.5)

32(9.8)

0.001

Diabetes, n(%)

138(32.3)

38(37.2)

100(30.8)

0.222

CHF, n(%)

49(11.5)

17(16.7)

32(9.8)

0.059

COPD, n(%)

77(1.6)

17(16.7)

60(18.5)

0.681

Peripheral, n(%)

70(1.6)

19(18.6)

51(15.7)

0.485

Heart rate, bpm

86.7 ± 14.5

89.6 ± 17.8

85.7 ± 13.2

0.019

MBP, mmHg

77.2 ± 8.1

75.3 ± 9.8

77.8 ± 7.4

0.007

SpO2, %

97.5 ± 2.2

96.7 ± 3.3

97.8 ± 1.6

0.000

*RASS score

0(− 2,0)

 − 0.5(− 3,0)

0(− 1,0)

0.128

Biochemistry

    

WBC, K/uL

14.1 ± 7.1

16.8 ± 8.7

13.3 ± 6.4

0.000

PLT, K/uL

220.7 ± 99.0

223.4 ± 101.5

219.8 ± 98.3

0.753

HGB, g/dl

10.8 ± 2.0

10.7 ± 1.9

10.8 ± 2.1

0.788

TB, mg/dl

1.1 ± 2.5

1.7 ± 4.8

0.9 ± 0.7

0.008

Glu, mg/dl

181.8 ± 105.1

229.9 ± 122.7

166.6 ± 94.2

0.000

Scr, mg/dl

1.3 ± 1.2

1.7 ± 1.2

1.2 ± 1.2

0.000

Potassium, mEq/L

4.3 ± 0.7

4.3 ± 0.7

4.3 ± 0.7

0.995

&Serum tropoin, ng/ml

4.3 ± 0.5

7.6 ± 1.3

2.9 ± 0.3

0.000

Treatments

    

Aspirin, n(%)

323(75.6)

55(53.9)

268(82.5)

0.000

Clopidogrel, n(%)

142(33.3)

28(27.4)

114(35.1)

0.154

Betablock, n(%)

257(83.6)

58(56.9)

299(92.0)

0.000

Stain, n(%)

287(67.2)

41(40.2)

246(75.7)

0.000

Vasopressor, n(%)

335(78.5)

94(92.2)

241(74.2)

0.000

Mechanical ventilation, n(%)

399(93.4)

96(94.1)

303(93.2)

0.752

#Revascularization, n(%)

299(70.0)

47(46.1)

252(77.5)

0.000

Propofol, n(%)

272(63.7)

45(44.1)

227(69.8)

0.000

Midazolam, n(%)

143(33.5)

56(54.9)

87(26.8)

0.000

Dexmedetomidine, n(%)

28(6.5)

2(2.0)

26(8.0)

0.032

Propofol + Midazolam

53(12.4)

17(16.6)

36(11.1)

0.135

Propofol + Dexmedetomidine

22(5.1)

1(1.0)

21(6.5)

0.036

Midazolam + Dexmedetomidine

13(3.0)

1(1.0)

12(3.7)

0.318

All three seditives

8(1.9)

0(0)

8(2.5)

0.207

  1. MI myocardial infarction; NSTEMI non-ST segment elevated myocardial infarction; AWSTEMI anterior wall ST segment elevated myocardial infarction; NAWSTEMI non-anterior wall ST segment elevated myocardial infarction; BMI body mass index; CHF congestive heart failure; COPD chronic obstructive pulmonary disease; MBP mean arterial pressure; WBC white blood cell; PLT platelet; HGB hemoglobin; TB total bilirubin; Glu glucose; Scr creatinine; *, 141 patients with RASS scores records, include 40 patients in mortality group and 101 in survival group; & 289 patients with serum tropoin record, include 201 patients in mortality group and 88 in survival group; #, include percutaneous coronary intervention and coronary artery bridge graft
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us